Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Dec;128(13):2200-2208.
doi: 10.1111/1471-0528.16894. Epub 2021 Sep 21.

Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study

Affiliations
Randomized Controlled Trial

Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study

M-L Marschalek et al. BJOG. 2021 Dec.

Abstract

Objective: To evaluate whether locally applied vaginal estrogen affects prolapse-associated complaints compared with placebo treatment in postmenopausal women prior to surgical prolapse repair.

Design: Randomised, double-masked, placebo-controlled, multicentre study.

Setting: Urogynaecology unit at the Medical University of Vienna and University Hospital of Tulln.

Population: Postmenopausal women with symptomatic pelvic organ prolapse and planned surgical prolapse repair.

Methods: Women were randomly assigned local estrogen cream or placebo cream 6 weeks preoperatively.

Main outcome measures: The primary outcome was differences in subjective prolapse-associated complaints after 6 weeks of treatment prior to surgery, assessed with the comprehensive German pelvic floor questionnaire. Secondary outcomes included differences in other pelvic floor-associated complaints (bladder, bowel or sexual function).

Results: Out of 120 women randomised, 103 (86%) remained for the final analysis. After 6 weeks of treatment the prolapse domain score did not differ between the estrogen and the placebo groups (4.4 ± 0.19 versus 4.6 ± 0.19; mean difference, -0.21; 95% CI -0.74 to 0.33; P = 0.445). Multivariate analysis, including only women receiving the intervention, showed that none of the confounding factors modified the response to estradiol.

Conclusions: These results demonstrate that preoperative locally applied estrogen does not ameliorate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse.

Tweetable abstract: Preoperative local estrogen does not ameliorate prolapse-associated symptoms in postmenopausal women with pelvic organ prolapse.

Keywords: Local estrogen therapy; pelvic organ prolapse; postmenopausal women.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of participants through the trial.

Comment in

References

    1. Basu M, Wise B, Duckett J. A qualitative study of women's preferences for treatment of pelvic floor disorders. BJOG 2011;118:338–44. - PubMed
    1. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997;89:501–6. - PubMed
    1. Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower uninary tract. Am J Obstet Gynecol 1981;141:817–20. - PubMed
    1. Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn 2011;30:754–7. - PubMed
    1. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra‐low‐dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–60. - PubMed

Publication types

Grants and funding